Discussion 'Cancer'
UltraCAR-T Therapy – Scope & Possibilities in Multiple Myeloma Management
Ongoing clinical trials are investigating the safety and efficacy of a new type of CAR T (Chimeric antigen receptor T-cells) therapy called UltraCAR-T therapy for myeloid malignancies. Unlike current CAR T cells, which utilize viruses to attach the CAR to…
Melflufen for Myeloma: A Deep Dive
The FDA recently granted priority review to a new drug application for melflufen (INN melphalan flufenamide), in combination with dexamethasone. Melflufen is intended for use as a first choice for patients with multiple myeloma whose disease is refractory to at…
ASH 2020 Updates: CAR T Cell Therapies in Multiple Myeloma
We kickstart the new year with a discussion on CAR T cells in myeloma treatment with a focus on the CT053, a CAR T-cell therapy targeting the BCMA protein and granted orphan drug status by the U.S. Food and Drug…
Novel Cancer Immunotherapies with SELLAS Life Sciences
The second episode of CureTalks with Gary discusses new immunotherapies with Sellas Life Sciences. Talking to Gary Petersen is Dr Angelos M. Stergiou CEO and President of Sellas Life Sciences and Senior Advisor for Sellas, Dr. Nicholas J Sarlis. Sellas…
Next Generation Targeted Cancer Therapies – The Cellectar Story!
CureTalks launches its new series featuring biotech companies at the cutting edge of innovation and breakthrough research with the purpose of bringing their contributions to the fore and informing the patient community. This talk series will be hosted by Gary…